Skip to main content

OrthoPediatrics Corp. Announces 1,000th Procedure Utilizing its Innovative Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”) System, the First Pediatric-Specific Solution Optimized to Treat Fractures and Deformities

Written by Customer Service on . Posted in Public Companies.

WARSAW, Ind., Sept. 03, 2020 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced completion of the 1,000th surgery utilizing its Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”), the first system specifically designed and developed to address the unique pediatric anatomies when treating femoral fractures and deformity correction procedures.
PNP | FEMUR, which received FDA 510(k) clearance in 2018, is an intramedullary nailing system to stabilize fractures and deformity correction osteotomies. It features a full suite of innovative instrumentation offering two distinct child and adolescent implant options optimized to handle the unique needs of small stature trauma and deformity procedures. The system’s enhanced child sized nails range from 7-9mm and the new adolescent sized nails range from 9-12mm. The PNP system offers the widest range of nail and screw options coupled with unique size specific nail features implanted through proprietary instrumentation; providing a full spectrum, all-inclusive system to treat children of any age and size. “We are proud of the innovative solutions that evolved from an impressive engineering team working closely with world renowned physician advisors to solve unmet pediatric patient and surgical needs. The PNP|FEMUR is actually OP’s 2nd generation nailing system, which improved upon almost a decade of learnings from the original PediNail system. Being the first to design and launch a pediatric nailing system, we have an obligation to take those learnings and improve,” commented Joe Hauser, Vice President of OrthoPediatrics’ Trauma & Deformity Correction business. “The thousandth implant represents a great milestone for our company, the many children that have been treated, and their families. Also, it displays our never-ending dedication to improving our own pediatric implant systems.”About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit www.orthopediatrics.com.Investor Contact
The Ruth Group
Emma Poalillo
(646) 536-7024
epoalillo@theruthgroup.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.